Price
CHART BY
Frequently asked questions
What is Tyra Biosciences's market capitalization?
What is the Earnings Per Share (EPS) for Tyra Biosciences?
What are the analyst ratings and target price for Tyra Biosciences's stock?
What is the EBITDA for Tyra Biosciences?
What is the free cash flow of Tyra Biosciences?
How many employees does Tyra Biosciences have, and what sector and industry does it belong to?
What is the free float of Tyra Biosciences's shares?
Financials
- Market Cap
- $1.38B
- EPS (TTM)
- -$1.88
- Free Float
- 36.44M
- EBITDA (TTM)
- -$125.43M
- Free Cashflow (TTM)
- -$91.20M
Pricing
- 52W span
- $6.42$26.27
Analyst Ratings
The price target is $33.00 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
- Employees
- 60
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- TYRA